Efektyvumas ir saugumas, gydant dimetilfumaratu ligonius, sergančius recidyvuojančia remituojančia išsėtine skleroze: gydymo patirtis Vilniaus išsėtinės sklerozės centre.

Dimethyl fumarate is a third oral therapy approved for the treatment of relapsing-remitting multiple sclerosis. Dimethyl fumarate and fumaric acid esters have been well known for many years as they are effective for the treatment of psoriasis. However, only a few years ago, two Phase III clinical trials have shown that dimethyl fumarate is also effective and safe in the treatment of relapsing-remitting multiple sclerosis. Since 2016, treatment with dimethyl fumarate is also available and compensated for patients in Lithuania. The drug is used to treat patients with first line treatment ineffective enough, contraindicated, or when side effects appear to first line treatment. The article presents the mechanism of action of dimethyl fumarate, its efficacy and safety in clinical trials and its place in a multiple sclerosis treatment algorithm. Patients treated with dimethyl fumarate at Vilnius university hospital Santaros klinikos and treatment appointment indications are reviewed; the efficacy and safety, as well as side effects of the drug that led to its discontinuation are evaluated. [ABSTRACT FROM AUTHOR]